Compare GSK plc (GSK) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Marriott International Inc — how do they compare? GSK plc trades at $50.33 (market cap $102.60B), while Marriott International Inc trades at $349.51 (market cap $91.14B). The key difference: GSK plc and Marriott International Inc are close in size by market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | MAR | |
|---|---|---|
Market Cap | $102.60B | $91.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $402.54 |
52-Week Low | $38.22 | $259.04 |
Enterprise Value | $123.04B | $108.45B |
Dividend Yield | 3.57% | 0.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Marriott International (MAR) trades at $355.34, up 1.98% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 9.62% net income margin and robust cash flow from operations of $3.21B in 2025, though its valuation remains elevated with a P/E of 36.18. Recent news highlights dividend declarations and AI-driven booking tools, while rising debt levels and Middle East weakness present challenges.
The outlook is mixed; analyst consensus leans bullish with a $387.31 price target, but high valuation and increasing debt-to-asset ratio (58.83% in 2025) cap upside potential. Key risks include regional volatility and competitive pressures, while fee revenue growth and a record pipeline offer opportunities for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
